Samuel R. Saks

Filings by Samuel R. Saks span 6 companies, the busiest being Jazz Pharmaceuticals plc, Tonix Pharmaceuticals Holding Corp. and PDL Biopharma, Inc. We count 41 filings; the first trade dates from 6 June 2007 and the latest from 26 February 2021.

Purchases make up the whole of the open-market record (22 purchases, €418k). The amount is not disclosed for 1 filing. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 9 share grants and 3 option exercises.

In size, the median ticket on the buying side is €9,267. For 20 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -12.4%. These figures describe past trades and do not predict future prices.

Most recently, on 26 February 2021, the filings show a share grant in Protagonist Therapeutics, Inc. The clock since the last published purchase (29 June 2016) now reads 3,769 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.